May 24, 2022
MediSieve Announces First Volunteer Successfully Enrolled in Phase 1 Clinical Study
Radboud University Medical Center is Conducting Safety Evaluation of MediSieve’s System for the Treatment of Acute Hyperinflammation.
LONDON, July 1, 2022 -- MediSieve today announced that the first volunteer had been enrolled in Phase 1 clinical study evaluating its Magnetic Haemofiltration System, a groundbreaking platform therapy which physically removes specific clinical targets from the bloodstream, as a potential treatment for IL-6-driven acute hyperinflammation. The System demonstrated a favourable safety and tolerability profile. The clinical study is being conducted at the Radboud University Medical Center, a leading Dutch medical institution. Prof. Peter Pickkers and Dr. Matthijs Kox, world experts on First-In-Man trials, are leading the study.
The Phase 1 study is a non-comparative study, evaluating the safety and initial performance of the MediSieve delivery system in healthy volunteers. The study is expected to enrol 8 female and male volunteers. Once the trial is completed, the data will be published in peer-reviewed scientific journals.
“This phase 1 trial is the first step in evaluating the use of MediSieve’s Magnetic Haemofiltration System for treatment of IL-6 driven hyperinflammation,” said Dr Matthijs Kox, lead investigator on the clinical trial. “The ability to selectively remove IL-6 and other targets without systemic drug exposure opens the door to treatment of a wide range of indications including ARDS, pancreatitis and post cardiac surgery.”
MediSieve’s pivotal IL-6 product is designed to treat acute cases of IL-6-driven hyperinflammation in patients with Cytokine storm, AKI, ARDS, CRS, Pancreatitis, Cardiac Surgery and others. High mortality and morbidity rates among patients with increased IL-6 levels place a considerable burden on healthcare systems around the world. Currently, systemic IL-6 inhibitors are the most popular form of treatment. However, because of their long-term immunosuppression, which makes patients more susceptible to both the initial infection and a later infection, these medications are inappropriate for the treatment of acute hyperinflammation. MediSieve's System allows for the selective elimination of hazardous compounds without the aforementioned side effects.
"This is a huge step for the company, and one that we have been working towards for many years,” said Cristina Blanco-Andujar, Ph.D., Chief Technology Officer of MediSieve. “We have for the first time tested our technology in humans and seen the dream of a founder transformed into reality. We are really excited to continue this clinical study and bring the benefits of Magnetic Haemofiltration to patients .
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: